Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Total Valuation
Arcturus Therapeutics has a market cap or net worth of $202.09M. The enterprise value is -$3.89M.
Market Cap$202.09M
Enterprise Value-$3.89M
Share Statistics
Arcturus Therapeutics has 28,423,069 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,423,069
Owned by Insiders8.05%
Owned by Institutions26.35%
Financial Efficiency
Arcturus Therapeutics’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 4.81%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.81%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee386.33K
Profits Per Employee-378.06K
Employee Count174
Asset Turnover0.25
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arcturus Therapeutics is 16.6. Arcturus Therapeutics’s PEG ratio is -0.83.
PE Ratio16.6
PS Ratio2.50
PB Ratio0.78
Price to Fair Value0.78
Price to FCF-2.26
Price to Operating Cash Flow-2.62
PEG Ratio-0.83
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 67.22M and earned 10.10M in profits. Earnings per share was -2.40.
Revenue67.22M
Gross Profit64.20M
Operating Income-74.95M
Pretax Income-65.78M
Net Income10.10M
EBITDA-71.93M
Earnings Per Share (EPS)-2.40
Cash Flow
In the last 12 months, operating cash flow was -74.27M and capital expenditures -455.66K, giving a free cash flow of -74.73M billion.
Operating Cash Flow-74.27M
Free Cash Flow-74.73M
Free Cash Flow per Share-2.63
Dividends & Yields
Arcturus Therapeutics pays an annual dividend of $0.06, resulting in a dividend yield of ―
Dividend Per Share$0.06
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.25
52-Week Price Change-50.24%
50-Day Moving Average7.29
200-Day Moving Average12.01
Relative Strength Index (RSI)40.50
Average Volume (3m)829.62K
Important Dates
Arcturus Therapeutics upcoming earnings date is May 11, 2026, After Close (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Arcturus Therapeutics as a current ratio of 6.64, with Debt / Equity ratio of 11.68%
Current Ratio6.64
Quick Ratio6.64
Debt to Market Cap0.03
Net Debt to EBITDA2.86
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Arcturus Therapeutics has paid -75.88M in taxes.
Income Tax-75.88M
Effective Tax Rate1.15
Enterprise Valuation
Arcturus Therapeutics EV to EBITDA ratio is 0.53, with an EV/FCF ratio of 0.51.
EV to Sales-0.57
EV to EBITDA0.53
EV to Free Cash Flow0.51
EV to Operating Cash Flow0.51
Balance Sheet
Arcturus Therapeutics has $230.91M in cash and marketable securities with $25.00M in debt, giving a net cash position of $205.91M billion.
Cash & Marketable Securities$230.91M
Total Debt$25.00M
Net Cash$205.91M
Net Cash Per Share$7.24
Tangible Book Value Per Share$7.81
Margins
Gross margin is 104.28%, with operating margin of -111.51%, and net profit margin of 15.02%.
Gross Margin104.28%
Operating Margin-111.51%
Pretax Margin-97.86%
Net Profit Margin15.02%
EBITDA Margin-107.01%
EBIT Margin-111.51%
Analyst Forecast
The average price target for Arcturus Therapeutics is $16.74, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.74
Price Target Upside135.44% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast-41.53%
EPS Growth Forecast-11.32%